CYDY - CytoDyn Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.5040
-0.0060 (-1.18%)
At close: 3:57PM EDT
Stock chart is not supported by your current browser
Previous Close0.5100
Open0.5076
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.5000 - 0.5130
52 Week Range0.0600 - 0.7100
Volume289,114
Avg. Volume447,550
Market Cap153.293M
Beta (3Y Monthly)0.75
PE Ratio (TTM)N/A
EPS (TTM)-0.2600
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.50
Trade prices are not sourced from all markets
  • GlobeNewswire6 days ago

    CytoDyn Reaches Historical Milestone, Submits First of Three Sections of BLA to FDA for Leronlimab (PRO 140) as a Combination Therapy for HIV

    CytoDyn Inc. (CYDY), (“CytoDyn” or the “Company”) a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, today announced that it has filed with the U.S. Food and Drug Administration (FDA) the non-clinical portion of its Biologics License Application (BLA) using the FDA’s Rolling Review process.  The non-clinical portion constitutes the first of three sections of the BLA submission for leronlimab (PRO 140) as a combination therapy with HAART for HIV-infected patients. The FDA previously granted Fast Track Designation (FTD) and recently granted Rolling Review for leronlimab (PRO140), which facilitates frequent interactions with the FDA review team.

  • GlobeNewswire13 days ago

    CytoDyn Reports Significant Reduction in Breast Cancer Tumor Metastasis in Preclinical Study and Requests FDA Fast Track Designation for Leronlimab (PRO 140) in Metastatic-Triple Negative Breast Cancer (mTNBC)

    CytoDyn Inc. (CYDY), (“CytoDyn” or the “Company”) a late stage biotechnology company developing a novel humanized CCR5 monoclonal antibody for multiple therapeutic indications, today announced that leronlimab (PRO 140), its lead investigational CCR5 inhibitor, showed significant reduction in the volume of human breast cancer tumor metastasis in a murine xenograft model. The metastatic tumor volume was reduced by more than 98% after 7 weeks. On that basis, CytoDyn has recently filed an application with the U.S. Food and Drug Administration (FDA) for Fast Track Designation for leronlimab (PRO 140) in mTNBC.

  • GlobeNewswire20 days ago

    FDA Grants Rolling Review for CytoDyn’s Planned BLA for Investigational HIV Therapy Leronlimab (PRO 140)

    CytoDyn Inc. (CYDY), a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, today announced that the FDA has reviewed and accepted CytoDyn’s request and plan to submit on a rolling basis its planned Biologics License Application (BLA).

  • GlobeNewswire25 days ago

    CytoDyn to Present New Data from Study of Investigational HIV Therapy Leronlimab (PRO 140), a Long-Acting, Single-Agent Maintenance Therapy at CROI 2019

    CytoDyn Inc. (OTC.QB: CYDY), a late stage biotechnology company developing a novel humanized CCR5 monoclonal antibody for multiple therapeutic indications, today announced that data from its study of leronlimab (PRO 140) is scheduled to be presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2019) on March 7, 2019.  Leronlimab is a once weekly, subcutaneous injection that blocks HIV-1 from entering and infecting human cells by binding to the CCR5 receptor with high affinity. The annual Conference on Retroviruses and Opportunistic Infections (CROI) brings together top basic, translational, and clinical researchers from around the world to share the latest studies, important developments, and best research methods in the ongoing battle against HIV/AIDS and related infectious diseases.  CROI 2019 will be held from March 4 to March 7, 2019, at the Washington State Convention Center in Seattle, Washington.

  • GlobeNewswirelast month

    Leronlimab (PRO 140) reduces by more than 98% human breast cancer metastasis in mouse xenografts for over 6 weeks

    CytoDyn Inc. (CYDY), a biotechnology company developing a novel humanized CCR5 monoclonal antibody for multiple therapeutic indications, announces that it was able to reduce by more than 98% the incidence of human breast cancer metastasis in a mouse xenograft model for cancer through six weeks with leronlimab (PRO 140). Based on these results, CytoDyn announced yesterday its plans for the expansion of pre-clinical animal studies into eight cancer indications, driven in part on prior research by Dr. Pestell suggesting that CCR5 inhibition may disrupt signaling and ultimately the spread of CCR5+ Circulating Tumor Cells (CTC’s).

  • GlobeNewswirelast month

    CytoDyn to Hold Investment Community Conference Call on February 25, 2019

    VANCOUVER, Washington, Feb. 19, 2019 -- CytoDyn Inc. (OTC.QB: CYDY) announces that Nader Pourhassan, Ph.D., director, President and CEO, and Richard Pestell, M.D., Ph.D.,.

  • GlobeNewswirelast month

    CytoDyn to Initiate 8 Pre-Clinical Animal Studies with Leronlimab (PRO 140) for Melanoma, Pancreatic, Breast, Prostate, Colon, Lung, Liver, and Stomach Cancer at an Estimated Cost of $1.5 million, which Could Lead to 8 Phase 2 Clinical Studies

    VANCOUVER, Washington, Feb. 19, 2019 -- CytoDyn Inc. (OTC.QB: CYDY), a biotechnology company developing a novel humanized CCR5 monoclonal antibody, leronlimab (PRO 140), for.

  • GlobeNewswirelast month

    Uptick Newswire Hosts CytoDyn Inc. on Their Stock Day Podcast to Discuss Revenue Expectations for 2020

    Uptick Newswire Stock Day Podcast welcomed CytoDyn Inc. (CYDY), a biotechnology company developing innovative treatments for multiple therapeutic indications based on leronlimab (PRO 140), a novel humanized monoclonal antibody targeting the CCR5 coreceptor. President and CEO, Dr. Nader Pourhassan, joined Stock Day host Everett Jolly. Dr. Pourhassan shared that the Company’s potential success in the treatments of cancer and HIV could represent a paradigm shift in the medical community, the data simply needs to be shown through human trials for various cancer indications, as they already have for HIV.

  • GlobeNewswirelast month

    CytoDyn to Present at BIO CEO & Investor Conference 2019 on February 11

    VANCOUVER, Washington, Feb. 08, 2019 -- CytoDyn Inc. (OTC.QB: CYDY), CytoDyn, a biotechnology company developing a novel humanized CCR5 monoclonal antibody for multiple.

  • GlobeNewswire2 months ago

    CytoDyn Announces Productive Conference Call with FDA Regarding First BLA Submission for Leronlimab (PRO 140) Combination Therapy at 700 mg Dose

    CytoDyn Inc. (CYDY), a biotechnology company developing new antibody therapies for combating human immunodeficiency virus (HIV) infection and potentially disrupting cancer metastasis, announces that it had a productive conference call meeting with the U.S. Food and Drug Administration (FDA) regarding its Biologics License Application (BLA) submission. This was the first follow-up meeting since its June 2018 pre-BLA meeting regarding the Company’s planned submission of its BLA and the positive interim data of its 700 mg monotherapy trial.

  • GlobeNewswire2 months ago

    CytoDyn to Deliver Presentation at NobleCon15 Conference

    CytoDyn Inc. (CYDY), a biotechnology company developing a novel humanized CCR5 monoclonal antibody for multiple therapeutic indications, today announced that it will be presenting an update on the company’s clinical development programs and objectives for leronlimab (PRO 140) during Noble Capital Markets’ 15th annual NobleCon Investor Conference on January 28, 2019 at 4:30 p.m. ET.

  • GlobeNewswire2 months ago

    Uptick Newswire Hosts The President and CEO of CytoDyn Inc. to Discuss The Incredible Potential Breakthroughs The Company is Working Towards in HIV and Cancer Treatment

    Uptick Newswire Stock Day Podcast welcomed CytoDyn Inc. (CYDY) (the “company”), which is a biotechnology company focused on the clinical development and potential commercialization of humanized monoclonal antibodies for the treatment and prevention of Human Immunodeficiency Virus (HIV) infection. At the start of the interview Jolly asked Pourhassan to bring listeners up to date on a few new board and management changes. Pourhassan said they’ve recently appointed Dr. Scott Kelly as chairman of the board.

  • GlobeNewswire2 months ago

    CytoDyn Appoints David F. Welch, Ph.D. to Board of Directors

    CytoDyn Inc. (CYDY), a biotechnology company developing a novel humanized CCR5 monoclonal antibody for multiple therapeutic indications, announces that David F. Welch, Ph.D., Founder, Chief Innovation Officer and Director of Infinera Corporation, has joined the CytoDyn Board of Directors.  Dr. Welch is an American businessman and research scientist who brings considerable strategic planning expertise and broad capital markets experience to the CytoDyn Board.  He is a significant investor in CytoDyn and understands leronlimab’s potential for targeting multiple disease processes.

  • GlobeNewswire2 months ago

    CytoDyn to Deliver Presentation at Biotech Showcase Conference

    CytoDyn Inc. (CYDY), a biotechnology company developing a novel humanized CCR5 monoclonal antibody for multiple therapeutic indications, today announced that it will be presenting an update on the company’s clinical development programs and objectives for leronlimab (PRO 140) during the Biotech Showcase on January 9, 2019 at 10:30 a.m. PT. The webcast will be available approximately one hour after the webcast presentation ends and is accessible for 90 days.

  • GlobeNewswire2 months ago

    CytoDyn Names Richard G. Pestell, M.D., Ph.D. as Vice Chairman of its Board of Directors

    VANCOUVER, Washington, Jan. 07, 2019 -- CytoDyn Inc. (OTC.QB: CYDY), a biotechnology company developing a novel humanized CCR5 monoclonal antibody for multiple therapeutic.

  • GlobeNewswire3 months ago

    CytoDyn Names Nitya G. Ray, Ph.D. as Chief Technology Officer

    VANCOUVER, Washington, Dec. 26, 2018 -- CytoDyn Inc. (OTC.QB: CYDY), a biotechnology company developing a novel humanized CCR5 monoclonal antibody for multiple therapeutic.

  • GlobeNewswire4 months ago

    CytoDyn to Hold Investment Community Conference Call on December 12, 2018

    VANCOUVER, Washington, Dec. 06, 2018 -- CytoDyn Inc. (OTC.QB: CYDY) announces that Nader Pourhassan, Ph.D., President and CEO, and Richard Pestell, M.D., Ph.D., F.A.C.P.,.

  • GlobeNewswire4 months ago

    CytoDyn’s Prostate Cancer Prognostic Test Demonstrates Substantial Added Value to Gleason Score in Predicting Patient Outcomes

    CytoDyn Inc. (CYDY) announces that results from a recent clinical study showed that CytoDyn’s PCaTest provides substantial additive discriminative value for predicting outcomes of patients diagnosed with prostate cancer compared to the Gleason score, the current standard for prostate cancer diagnosis. The positive clinical data from two groups totaling 218 patients and followed for 10 years adds to three prior clinical studies conducted in more than 350 patients that demonstrated a high predictive value for CytoDyn’s PCaTest in determining outcome of men diagnosed with prostate cancer.

  • GlobeNewswire4 months ago

    CytoDyn to Present at Two Investment Conferences in December

    A live webcast and replay of the presentation at the LD Micro Main Event will be available on the Investors section of the Company’s website, http://ir.cytodyn.com/. Leronlimab (PRO 140) is a humanized IgG4 monoclonal antibody that blocks CCR5, a cellular receptor that plays multiple roles with implications in HIV infection, tumor metastasis, and immune signaling.

  • GlobeNewswire4 months ago

    USAN Council Assigns Leronlimab as the Official Name for CytoDyn’s PRO 140

    CytoDyn Inc. (CYDY), a biotechnology company developing a novel humanized CCR5 monoclonal antibody for multiple therapeutic indications, announces that the United States Adopted Names (USAN) Council has adopted leronlimab as the official name for PRO 140.  Leronlimab is an investigational new drug and has not yet been approved for any indication.

  • GlobeNewswire4 months ago

    CytoDyn Completes Acquisition of ProstaGene and Names Dr. Richard G. Pestell to Board of Directors

    CytoDyn Inc. (CYDY), a biotechnology company developing a novel humanized CCR5 monoclonal antibody for multiple therapeutic indications, announces that on Friday November 16, 2018 it completed the previously announced acquisition of privately held ProstaGene, LLC. Concurrently, Richard G. Pestell, M.D., Ph.D., M.B.A., F.A.C.P., F.R.A.C.P., founder and former Chief Executive Officer of ProstaGene, has been appointed to the CytoDyn board of directors and named Chief Medical Officer with responsibility for leading all PRO 140 (leronlimab) programs in non-HIV indications. Dr. Pestell has served as the Company’s Interim Chief Medical Officer since August 2018. “Richard is a driving force in CCR5 antagonist research and we gain significant expertise and intellectual property with this acquisition that advances the development of PRO 140 as a novel cancer metastasis therapeutic,” said Anthony D. Caracciolo, CytoDyn’s Chairman.